Combination of CTLA-4 and PD-1 blockers for treatment of cancer. (Q64910760)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

review article

4 references

23 September 2020

8 February 2021

17 October 2022

Combination of CTLA-4 and PD-1 blockers for treatment of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

antineoplastic combined chemotherapy protocols

1 May 2020

main subject

1 reference

23 September 2020

1 reference

8 February 2021

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

author name string

Anand Rotte

series ordinal

1

1 reference

http://europepmc.org/abstract/PMC/6567914

30 June 2019

publication date

13 June 2019

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

23 September 2020

8 February 2021

17 October 2022

Journal of Experimental & Clinical Cancer Research

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

23 September 2020

8 February 2021

17 October 2022

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

page(s)

255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

1 May 2020

copyright license

3 references

23 September 2020

8 February 2021

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

17 October 2022

cites work

1 reference

12 December 2020

A new member of the immunoglobulin superfamily--CTLA-4

1 reference

12 December 2020

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

12 December 2020

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1 reference

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

Regulation of CTLA-4 expression during T cell activation

1 reference

12 December 2020

Regulation of surface and intracellular expression of CTLA4 on mouse T cells

1 reference

12 December 2020

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

1 reference

12 December 2020

CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells

1 reference

12 December 2020

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

1 reference

12 December 2020

CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression

1 reference

12 December 2020

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

1 reference

12 December 2020

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

12 December 2020

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

1 reference

12 December 2020

PD-1: an inhibitory immunoreceptor involved in peripheral tolerance

1 reference

12 December 2020

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses

1 reference

12 December 2020

B7-independent inhibition of T cells by CTLA-4.

1 reference

12 December 2020

PD-1 and its ligands in tolerance and immunity

1 reference

12 December 2020

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

1 reference

12 December 2020

CTLA-4 control over Foxp3+ regulatory T cell function

1 reference

12 December 2020

CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death

1 reference

12 December 2020

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

12 December 2020

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

The PD-1 pathway in tolerance and autoimmunity

1 reference

12 December 2020

Interleukin-2 receptor signaling: at the interface between tolerance and immunity

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management

1 reference

12 December 2020

IL-2: the first effective immunotherapy for human cancer.

1 reference

12 December 2020

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 December 2020

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

12 December 2020

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

1 reference

12 December 2020

Immunotherapy of melanoma: present options and future promises.

1 reference

12 December 2020

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

12 December 2020

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

1 reference

12 December 2020

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

12 December 2020

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

1 reference

12 December 2020

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

12 December 2020

1 reference

12 December 2020

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

12 December 2020

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

12 December 2020

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

12 December 2020

Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

1 reference

12 December 2020

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial

1 reference

12 December 2020

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

1 reference

12 December 2020

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

1 reference

12 December 2020

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

1 reference

12 December 2020

Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.

1 reference

12 December 2020

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

1 reference

12 December 2020

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

1 reference

12 December 2020

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

1 reference

12 December 2020

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

1 reference

12 December 2020

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

12 December 2020

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

1 reference

12 December 2020

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

1 reference

12 December 2020

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

1 reference

12 December 2020

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

1 reference

12 December 2020

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience

1 reference

12 December 2020

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

1 reference

12 December 2020

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

1 reference

12 December 2020

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

1 reference

12 December 2020

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

1 reference

12 December 2020

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

1 reference

12 December 2020

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

1 reference

12 December 2020

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

1 reference

12 December 2020

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

1 reference

12 December 2020

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.

1 reference

12 December 2020

PD-1 blockade with nivolumab in endemic Kaposi sarcoma.

1 reference

12 December 2020

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

1 reference

12 December 2020

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

1 reference

12 December 2020

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.

1 reference

12 December 2020

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

1 reference

12 December 2020

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

1 reference

12 December 2020

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

1 reference

12 December 2020

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

1 reference

12 December 2020

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

1 reference

12 December 2020

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

1 reference

12 December 2020

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients.

1 reference

12 December 2020

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

1 reference

12 December 2020

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

1 reference

12 December 2020

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

1 reference

12 December 2020

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

1 reference

12 December 2020

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

1 reference

12 December 2020

Nobel committee honors tumor immunologists

1 reference

12 December 2020

Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies

1 reference

12 December 2020

Immune checkpoint inhibitors: recent progress and potential biomarkers

1 reference

12 December 2020

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

1 reference

12 December 2020

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

1 reference

12 December 2020

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

1 reference

12 December 2020

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

1 reference

12 December 2020

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

1 reference

12 December 2020

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

1 reference

12 December 2020

Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses

1 reference

12 December 2020

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

1 reference

12 December 2020

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

1 reference

12 December 2020

10.1186/S13046-019-1259-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31196207%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

1 reference